Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
MRSNCAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
MRSNCAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025.
Mersana Therapeutics Announces Additional Interim Phase 1 Clinical Data For Emiltatug Ledadotin, B7-H4-Directed Dolasynthen ADC
MRSNTruist Securities Maintains Buy on Mersana Therapeutics, Raises Price Target to $10
MRSNMersana Therapeutics Q1 EPS $(0.19), Inline, Sales $2.75M Miss $5.84M Estimate
MRSNAn Overview of Mersana Therapeutics's Earnings
MRSNMersana Therapeutics Implements Strategic Restructuring And Reprioritization Plan To Extend Cash Runway, Advance Emi-Le; XMT-1660
MRSNMersana Therapeutics Announces Upcoming Emi-Le; XMT-1660 Oral and Poster Presentations at ASCO 2025 Annual Meeting
MRSNMersana Therapeutics Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $16.36M Beat $7.71M Estimate
MRSNMersana Therapeutics Receives Nasdaq Non-Compliance Notice
MRSNWhy Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
MRSNMersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast cancer.
Mersana Therapeutics Announces Phase 1 Data for Lead ADC Candidate Targeting B7-H4 in Cancer Treatment
MRSNMersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
MRSNThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).
Mersana Therapeutics shares were trading higher after the company's XMT-1660 was granted FDA Fast Track Designation for treatment of triple-negative breast cancer.
MRSNMersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer
MRSN